BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 10 2024 - 7:30AM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the
“Company”), a commercial-stage biopharmaceutical company focused on
genetic diseases and cancers, today announced that on June 6, 2024,
the compensation committee of BridgeBio’s board of directors
approved equity grants to 18 new employees in restricted stock
units for an aggregate of 90,591 shares of the Company’s common
stock. One-fourth of the shares underlying each employee’s
restricted stock units will vest on May 16, 2025, with one-twelfth
of the remaining shares underlying each such employee’s restricted
stock units vesting on a quarterly basis thereafter, in each case,
subject to each such employee’s continued employment with the
Company or one of its subsidiaries on such vesting dates. All of
the above-described awards were made under BridgeBio’s Amended and
Restated 2019 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the Company
in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted
pursuant to the terms of the Plan. The Plan was adopted by
BridgeBio’s board of directors in November 2019, and amended and
restated on February 10, 2023 and on December 13, 2023.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical
company founded to discover, create, test, and deliver
transformative medicines to treat patients who suffer from genetic
diseases and cancers with clear genetic drivers. BridgeBio’s
pipeline of development programs ranges from early science to
advanced clinical trials. BridgeBio was founded in 2015 and its
team of experienced drug discoverers, developers and innovators are
committed to applying advances in genetic medicine to help patients
as quickly as possible. For more information visit bridgebio.com
and follow us on LinkedIn and Twitter.
BridgeBio Contact:
Vikram Balicontact@bridgebio.com(650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Jul 2024 to Aug 2024
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Aug 2023 to Aug 2024